Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Olema Pharmaceuticals (OLMA) Operating Leases (2021 - 2025)

Olema Pharmaceuticals (OLMA) has 5 years of Operating Leases data on record, last reported at $69000.0 in Q4 2025.

  • On a quarterly basis, Operating Leases fell 73.15% to $69000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $69000.0, a 73.15% decrease, with the full-year FY2025 number at $69000.0, down 73.15% from a year prior.
  • Operating Leases reached $69000.0 in Q4 2025 per OLMA's latest filing, down from $310000.0 in the prior quarter.
  • Over the last five years, Operating Leases for OLMA hit a ceiling of $2.4 million in Q4 2021 and a floor of $69000.0 in Q4 2025.
  • A 5-year average of $1.1 million and a median of $1.2 million in 2023 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: decreased 2.69% in 2023, then crashed 89.32% in 2025.
  • Tracing OLMA's Operating Leases over 5 years: stood at $2.4 million in 2021, then tumbled by 34.27% to $1.5 million in 2022, then fell by 7.81% to $1.4 million in 2023, then tumbled by 82.02% to $257000.0 in 2024, then plummeted by 73.15% to $69000.0 in 2025.
  • Business Quant data shows Operating Leases for OLMA at $69000.0 in Q4 2025, $310000.0 in Q3 2025, and $602000.0 in Q2 2025.